Circulation · 2019 · 54 citations · 34 references
Life SciencesImmunologyPathobiologyCellular ImmunologyImmunoregulationMolecular ImmunologyCardiovascular DiseaseImmune Cell PhysiologyLipoprotein MetabolismNuclear ReceptorsT Cell BiologyAnimal Disease ModelsAtherosclerosis Molecular MechanismsAtherosclerosis RiskInflammation In Cardiovascular DiseaseLow-density Lipoprotein Receptor FamilyPlaque InflammationSubclinical AtherosclerosisTh17 Cell Differentiation
BACKGROUND: Although the role of Th17 and regulatory T cells in the progression of atherosclerosis has been highlighted in recent years, their molecular mediators remain elusive. We aimed to evaluate the association between the CD69 receptor, a regulator of Th17/regulatory T cell immunity, and atherosclerosis development in animal models and in patients with subclinical disease. METHODS: Low-density lipoprotein receptor-deficient chimeric mice expressing or not expressing CD69 on either myeloid or lymphoid cells were subjected to a high fat diet. In vitro functional assays with human T cells were performed to decipher the mechanism of the observed phenotypes. Expression of CD69 and NR4A nuclear receptors was evaluated by reverse transcription-polymerase chain reaction in 305 male participants of the PESA study (Progression of Early Subclinical Atherosclerosis) with extensive (n=128) or focal (n=55) subclinical atherosclerosis and without disease (n=122). RESULTS: After a high fat diet, mice lacking CD69 on lymphoid cells developed large atheroma plaque along with an increased Th17/regulatory T cell ratio in blood. Oxidized low-density lipoprotein was shown to bind specifically and functionally to CD69 on human T lymphocytes, inhibiting the development of Th17 cells through the activation of NR4A nuclear receptors. Participants of the PESA study with evidence of subclinical atherosclerosis displayed a significant CD69 and NR4A1 mRNA downregulation in peripheral blood leukocytes compared with participants without disease. The expression of CD69 remained associated with the risk of subclinical atherosclerosis in an adjusted multivariable logistic regression model (odds ratio, 0.62; 95% CI, 0.40-0.94; P=0.006) after adjustment for traditional risk factors, the expression of NR4A1, the level of oxidized low-density lipoprotein, and the counts of different leucocyte subsets. CONCLUSIONS: CD69 depletion from the lymphoid compartment promotes a Th17/regulatory T cell imbalance and exacerbates the development of atherosclerosis. CD69 binding to oxidized low-density lipoprotein on T cells induces the expression of anti-inflammatory transcription factors. Data from a cohort of the PESA study with subclinical atherosclerosis indicate that CD69 expression in PBLs inversely correlates with the presence of disease. The expression of CD69 remained an independent predictor of subclinical atherosclerosis after adjustment for traditional risk factors.
34
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text
Natural regulatory T cells control the development of atherosclerosis in mice
Hafid Ait‐Oufella, Benoı̂t L. Salomon, Stéphane Potteaux et al. · Nature Medicine · 2006 · 1.1K citations
Life Sciences, Immunology, Pathology +12
Mercedes Ricote, Jannet T. Huang, Lluís Fajas et al. · Proceedings of the National Academy of Sciences · 1998 · 721 citations · Full text
Control of TH17 cells occurs in the small intestine
Enric Esplugues, Samuel Huber, Nicola Gagliani et al. · Nature · 2011 · 652 citations